Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. lessened its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 11.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 88,371 shares of the specialty pharmaceutical company's stock after selling 11,577 shares during the period. Alliancebernstein L.P. owned approximately 0.15% of Jazz Pharmaceuticals worth $10,883,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Centre Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at $9,335,000. Moloney Securities Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth about $464,000. Franklin Resources Inc. boosted its position in Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock valued at $124,208,000 after buying an additional 48,708 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Jazz Pharmaceuticals by 13.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company's stock worth $4,420,000 after buying an additional 4,332 shares during the period. Finally, Sanctuary Advisors LLC increased its holdings in Jazz Pharmaceuticals by 502.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 11,754 shares of the specialty pharmaceutical company's stock worth $1,310,000 after buying an additional 9,804 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JAZZ. Royal Bank of Canada decreased their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Piper Sandler restated an "overweight" rating and issued a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Morgan Stanley reaffirmed an "overweight" rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $187.71.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock traded up $0.57 on Monday, hitting $101.07. 450,929 shares of the company were exchanged, compared to its average volume of 781,482. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $6.14 billion, a price-to-earnings ratio of 14.24, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The company has a 50-day moving average price of $129.67 and a 200 day moving average price of $122.77.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now owns 439,744 shares of the company's stock, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Patricia Carr sold 4,813 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now owns 8,237 shares of the company's stock, valued at approximately $1,189,587.54. This represents a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock worth $4,023,305 in the last three months. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.